moatshark My

All holdings

Exelixis

EXEL

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$544k
Combined value at quarter end
Last quarter
0 bought
0 sold or trimmed
Price at Q2 ’26 end
$54.41
+26.9% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+15.5%Q3 ’24
+28.3%Q4 ’24
+10.9%Q1 ’25
+19.4%Q2 ’25
-6.3%Q3 ’25
+6.1%Q4 ’25
-2.1%Q1 ’26
+26.9%Q2 ’26
Q3 ’24: +15.5%; Q4 ’24: +28.3%; Q1 ’25: +10.9%; Q2 ’25: +19.4%; Q3 ’25: -6.3%; Q4 ’25: +6.1%; Q1 ’26: -2.1%; Q2 ’26: +26.9%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Exelixis.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Exelixis
First Eagle Investment Management0.0%$544k$544kUnchanged12 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Exelixis
Bought or soldFiling
10 Aug 2026Beckerle Mary CDirector▼ Sold9,812$53.66$527kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
1 January
Shares outstanding
248m at 27 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$31.3m2013
$37.2m2015
$452m2017
$968m2019
$1.4bn2021
$1.8bn2023
$2.3bn2025
2013: $31.3m; 2014: $25.1m; 2015: $37.2m; 2016: $191m; 2017: $452m; 2018: $854m; 2019: $968m; 2020: $988m; 2021: $1.4bn; 2022: $1.6bn; 2023: $1.8bn; 2024: $2.2bn; 2025: $2.3bn
Exelixis revenue and net income by year
YearRevenueNet income
2025$2.3bn$783m
2024$2.2bn$521m
2023$1.8bn$208m
2022$1.6bn$182m
2021$1.4bn$231m
2020$988m$112m
2019$968m$321m
2018$854m$690m
2017$452m$154m
2016$191m−$70.2m
2015$37.2m−$162m
2014$25.1m−$261m
2013$31.3m−$238m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.